Clinical investigation of hearing impairment in cytomegalovirus hepatitis and the curative effect of ganciclovir

Abstract

Abstract: AIM:To analyze the hearing impairment rate of cytomegalovirus (CMV)hepatitis and explore the curative effect of ganciclovir.METHODS: 103 cases of CMV hepatitis patients were randomly divided into treatment group (65 cases)and control group (38 cases).Treatment group used Ganciclovir, supplemented symptomatic treatment, the control group used only symptomatic treatment.The blood, biochemical routine, levels of blood CMV-pp65and urine CMVDNA were determined regularly, and the brain stem auditory evoked potential (ABR)was detected.RESULTS: The positive rate of CMV-pp65, CMV-DNA of patients before and after treatment in treatment group had significant difference (P<0.01);The changes of positive rate of CMV-pp65and urine CMV-DNA before and after treatment in control group had no significant difference (P>0.05).The ABR of 103 cases of CMV hepatitis patients was tested before treatment, 27 ears were hearing impairment (13.1%).There were 17 ears hearing impairment (13.08%)in treatment group 65 cases patients, and 10ears hearing impairment (13.16%)in control group 38 cases patients, after one yearwith ganciclovir treatment, 15 ears were hearing impairment (11.54%)in treatment group and 17 ears were hearing impairment (22.37%)in control group.Compared with the two groups, the rate of hearing impairment had significant difference (P<0.05). CONCLUSION:There are the hearing impairment in part of children with CMV hepatitis, after Ganciclovir treatment the blood CMV-pp65and urine CMV-DNA in patients were negative and the incidence of hearing impairment was decreased.

Key words: cytomegalovirus, hearing impairment, brain stem auditory evoked potential

CLC Number:

XU Zhi-wei, WANG Hong-jiao, CHEN Jun-ya, CHEN Yi-ping. Clinical investigation of hearing impairment in cytomegalovirus hepatitis and the curative effect of ganciclovir[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(8): 926-929.

References 13

[1]	Retiè re C, Prod'homme V, Imbert-Marcille BM, et al. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1proteins:a tool to study the fine specificity of the antiviral response[J].J Virol, 2000, 74(9):3948-3952.
[2]	Fowler KB, Dable AJ, Boppana SB, et al.Newborn hearing screening :will children with hearing loss caused by congenital cytomegalovirus infection be missed[J] ? J Pediatr, 1999, 135(1):60-64.
[3]	Dahle AJ, Fowler KB, Wright JD, et al.Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus[J].J Am Acad Audiol, 2000, 11(5): 283-290.
[4]	Fowler KB, McCollister FP, Dohle AJ, et al.Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegaloirus infection[J].J Pediatr, 1997, 130(4):624-630.
[5]	Dunduroz R, Akin R, Okutan V, et al.Acquired cytomegalovirus infection in infants.A case successfully treated with ganciclovir[J].Presse Med, 1997, 26(21):1000-1001.
[6]	Fischler B.Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis[J].J Pediatr Gastroenterol Nutr, 2002, 34(2):154-157.
[7]	朴春姬.更昔洛韦治疗婴儿巨细胞病毒性肝炎疗效观察[J].中国优生与遗传杂志, 2007, 15(1):109.
[8]	MichaelsMG, Greenberg DP, Sabo DL, et al.Treatment of children with congenital cytomegalovirus infection with · 928· Chin J Clin Pharmacol Ther 2008 Aug;13(8)ganciclovir[J].Pediatr Infect Dis J, 2004, 23(1):88-89.
[9]	方峰, 董永绥.巨细胞病毒和巨细胞病毒感染的诊断[J].中华儿科杂志, 1999, 37(7):397-399.
[10]	Williamson WD, Demmler GJ, Percy AK, et al.Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection[J].Pediatrics, 1992, 90(6): 862-866.
[11]	Sugiura S, Yoshikawa T, Nishiyama Y, et al.Detection of herpesvirus DNAs in perilymph obtained from patients with sensorineural hearing loss by real-time polymerase chain reaction[J].Laryngoscope, 2004, 114(12):2235-2238.
[12]	Williamson WD, Demmler GJ, Percy AK, et al.Progressive hearing loss in infants with asymp-tomatic congenital cytomegalovirus infection[J].Pediatrics, 1992, 90(6): 862-866.
[13]	Vancikova Z, Kucerova T, Pelikan L, et al.Perinatal cytomegalovirus hepatitis:to treat or not to treat with ganciclovir[J].J Paediatr Child Health, 2004, 40(8):444-448.

[1]	QI Linling, LIU Shourong. Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 578-582.
[2]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[3]	TAO Chengjing, LIU Shourong, CHENG Xiaoxian, HU Jiannv, BAI Xiuli, ZHANG Suying, ZHAO Chun, ZUO Zhongbao. Effects of different postpartum withdrawal time of tenofovir on hepatitis B virus markers, virology and biochemical indexes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1146-1152.
[4]	LI Qian, LV Hong, LIU Yue, SHI Jia. Efficacy and safety of antifibrinolytic therapy in the perioperative cardiovascular surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 830-835.
[5]	WANG Nana, TAN Xiaofeng, MA Tao, CHENG Yusheng. Current situation and future perspectives of treatment of chronic pulmonary aspergillosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 217-222.
[6]	LI Hongpeng, ZHANG Liu, LI Qingyun. Mechanism and advance of COVID-19 on immune related pathogenesis and immunotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1288-1294.
[7]	WANG Weilu, MAO Yicheng, ZHU Yizhun. Research progress of autophagy in viral pneumonia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1315-1320.
[8]	MU Xin, ZHAO Ying, ZHANG Lan, CUI Yimin, ZHANG Yongxiang, DU Guanhua. Drug clinical trial of COVID-19 in China: A brief analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 869-877.
[9]	ZHANG Zhengfu, LI Meng, WANG Jianan. Protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 421-425.
[10]	LIU Qi, XIA Shuai, JIANG Shibo. Research and development of antiviral drugs against new coronavirus 2019-nCoV [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 241-245.
[11]	CUI Cheng, YAO Xueting, TU Siqi, XIE Jieen, LI Haiyan, LIU Dongyang. Advances of the clinical pharmacology of hydroxychloroquine sulfate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 221-226.
[12]	LUO Yi, JIANG Zhiwei. Statistical consideration in the design of COVID-19 clinical trials in emergency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 121-125.
[13]	LAN Qiaoshuai, XIA Shuai, ZHOU Jie, WANG Qian, LU Lu. New use of old drugs in the treatment of SARS-CoV-2 infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 126-134.
[14]	HU Ke. New coronavirus pneumonia: Question and confusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 141-143.
[15]	HUANG Xinyi, GUO Fei, ZENG Xiangchang, OUYANG Dongsheng. Short-chain fatty acids as signal molecules in intestinal inflammation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1293-1299.